Literature DB >> 27686814

In vitro cytotoxic and genotoxic evaluation of peptides used in nuclear medicine (DOTATATE and Ubiquicidin29-41) in CHO-K1 cells.

Ivette Zegarra Ocampo1, Priscila de Queiroz Souza Passos2, Luma Ramirez de Carvalho1, Camila Ayala Lira da Cruz1, Natália Mencacci Esteves-Pedro2, Fabiana Medeiros da Silva2, Olga Zazuco Higa1,2, Luiz Alberto Pereira Dias3, Kayo Okazaki1, Daniel Perez Vieira4.   

Abstract

Micronucleus (MN) assay constitutes a valuable surrogate to the chromosome aberration technique for in vitro testing of the genotoxicity of substances. As test substances, two peptidic compounds (DOTATATE and Ubiquicidin29-41) used in nuclear medicine, were tested for in vitro cytotoxicity and genotoxicity in CHO-K1 cells. None of the compounds showed detectable cytotoxicity (0.5-7.3 ng/mL for DOTATATE and 0.3-4.5 ng/mL for UBI29-41), genotoxicity (0.72, 7.2 and 72.0 ng/ml for DOTATATE and 0.45, 4.5 and 45.0 ng/mL for UBI29-41) or cell cycle changes as compared to untreated controls at the concentrations tested. Statistical analysis showed good concordance between two independent analysts. The results corroborate the notion of the safety of the compounds and present improvements of the in vitro MN assay when performed in a pre-clinical trial context that increase the throughput of small-to-medium testing facilities as an alternative to high content screening systems.

Entities:  

Keywords:  CHO-K1 cell; Cytotoxicity; DOTATATE, Ubiquicidin29-41; Genotoxicity; Modified micronucleus assay

Year:  2016        PMID: 27686814      PMCID: PMC5101300          DOI: 10.1007/s10616-016-0024-9

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  35 in total

Review 1.  Current status of biodosimetry based on standard cytogenetic methods.

Authors:  Marcela Maria Pereira de Lemos Pinto; Neyliane Frassinetti Gonçalves Santos; Ademir Amaral
Journal:  Radiat Environ Biophys       Date:  2010-07-09       Impact factor: 1.925

2.  The evaluation of micronucleus frequency by acridine orange fluorescent staining in peripheral blood of rats treated with lead acetate.

Authors:  Ayla Celik; Oya Ogenler; Ulkü Cömelekoglu
Journal:  Mutagenesis       Date:  2005-08-31       Impact factor: 3.000

3.  Reflections on the development of micronucleus assays.

Authors:  John A Heddle; Michael Fenech; Makoto Hayashi; James T MacGregor
Journal:  Mutagenesis       Date:  2010-10-27       Impact factor: 3.000

4.  Giemsa versus acridine orange staining in the fish micronucleus assay and validation for use in water quality monitoring.

Authors:  T Polard; S Jean; G Merlina; C Laplanche; E Pinelli; L Gauthier
Journal:  Ecotoxicol Environ Saf       Date:  2010-09-15       Impact factor: 6.291

Review 5.  Radiotracers for fungal infection imaging.

Authors:  Antonella Lupetti; Mark G J de Boer; Paola Erba; Mario Campa; Peter H Nibbering
Journal:  Med Mycol       Date:  2010-08-26       Impact factor: 4.076

6.  Effect of Brazilian propolis (AF-08) on genotoxicity, cytotoxicity and clonogenic death of Chinese hamster ovary (CHO-K1) cells irradiated with (60)Co gamma-radiation.

Authors:  Geyza Spigoti Santos; Shigetoshi Tsutsumi; Daniel Perez Vieira; Paolo Bartolini; Kayo Okazaki
Journal:  Mutat Res Genet Toxicol Environ Mutagen       Date:  2014-02-11       Impact factor: 2.873

Review 7.  Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer.

Authors:  S M Okarvi
Journal:  Cancer Treat Rev       Date:  2007-09-17       Impact factor: 12.111

8.  Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.

Authors:  Stephen A Deppen; Eric Liu; Jeffrey D Blume; Jeffrey Clanton; Chanjuan Shi; Laurie B Jones-Jackson; Vipul Lakhani; Richard P Baum; Jordan Berlin; Gary T Smith; Michael Graham; Martin P Sandler; Dominique Delbeke; Ronald C Walker
Journal:  J Nucl Med       Date:  2016-01-14       Impact factor: 10.057

9.  Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.

Authors:  Bernhard Nilica; Dietmar Waitz; Vlado Stevanovic; Christian Uprimny; Dorota Kendler; Sabine Buxbaum; Boris Warwitz; Llanos Gerardo; Benjamin Henninger; Irene Virgolini; Margarida Rodrigues
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-02-27       Impact factor: 9.236

Review 10.  Small Molecule Radiopharmaceuticals - A Review of Current Approaches.

Authors:  Shubhra Chaturvedi; Anil K Mishra
Journal:  Front Med (Lausanne)       Date:  2016-02-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.